Bernard Nsengimana

Mr. Bernard Nsengimana

Henan University
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
BNBernard Nsengimana
Bernard Nsengimana
FKFaiz Ali Khan
Faiz Ali Khan
ENEbenezeri Erasto Ngowi
Ebenezeri Erasto Ngowi
XZXuefeng Zhou
Xuefeng Zhou
YJYu Jin
Yu Jin
SJShaoping Ji
Shaoping Ji

20 October 2022 in Gene & Protein in Disease
Verified
Journal Article
Open access
PDF file
FKFaiz Ali Khan
Faiz Ali Khan
BNBernard Nsengimana
Bernard Nsengimana
NKNazeer Khan
Nazeer Khan
JHJingjing Huang
Jingjing Huang
HGHaojie Guo
Haojie Guo
SJShaoping Ji
Shaoping Ji
Since decades ago, circular RNAs (circRNAs) have been known for their critical role in RNA maturation, RNA transportation, epigenetic regulation, gene transcription, peptide/protein translation, and interaction with proteins to modulate their activities. At present, circRNAs are being extensively studied as oncotargets in the onset and development of several malignancies and treatment resistance by modulating various signaling pathways and cellular processes such as ubiquitination, degradation, invasion, proliferation, c-Myc oncoprotein stabilization, epithelial-mesenchymal transition, autophagy, and apoptosis. In addition, circRNAs are known to be highly conserved, have a longer life span than other RNAs, and their differential expressions are implicated in solid tumors and hematological malignancies. However, their potential diagnostic and therapeutic targets are not fully elucidated. Therefore, we sought to underline the opportunities and constraints associated with using these oncotargets in cancer therapy by outlining the functional mechanisms of circRNAs and their ectopic expression in distinct malignancies. The clinical applications of circRNAs in developing progressive markers like liquid biopsy biomarkers and for treating cancers are also prospected in this paper.

17 October 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MKMatthew Klos
Matthew Klos
WHWanqing Hou
Wanqing Hou
BNBernard Nsengimana
Bernard Nsengimana
SWShiwang Weng
Shiwang Weng
CYChuyun Yan
Chuyun Yan
SHShuxin Han
Shuxin Han
Beta-hydroxybutyrate (βOHB), along with acetoacetate and acetone, are liver-produced ketone bodies that are increased after fasting or prolonged exercise as an alternative fuel source to glucose. βOHB, as the main circulating ketone body, is not only a G-protein coupled receptor ligand but also a histone deacetylases inhibitor, prompting the reexamination of its role in health and disease. In this study, we compared the effects of two commercial βOHB formulations an enantiomer R βOHB and a racemic mixture ±βOHB on induced pluripotent stem cell cardiac myocytes (iPS-CMs) electrophysiology. Cardiac myocytes were cultured in R βOHB or ±βOHB for at least ten days after lactate selection. Flouvolt or Fluo-4 was used to assay iPS-CMs electrophysiology. We found that while both formulations increased the optical potential amplitude, R βOHB prolonged the action potential duration but ±βOHB shortened the action potential duration. Moreover, ±βOHB increased the peak calcium transient but R βOHB reduced the peak calcium transient. Co-culturing with glucose or fatty acids did not ameliorate the effects, suggesting that βOHB was more than a fuel source. The effect of βOHB on iPS-CMs electrophysiology is most likely stereoselective, and care must be taken to evaluate the role of exogenous βOHB in health and disease.

1 September 2021 in Preprints.org
Verified
Preprint
Open access
BNBernard Nsengimana
Bernard Nsengimana
FNFrancois Nkurunziza
Francois Nkurunziza
WNWivine Mudahigwa Ntaganira
Wivine Mudahigwa Ntaganira
RURuth Uzayisenga
Ruth Uzayisenga
GRGad Rutayisire
Gad Rutayisire
Several factors enhance the possibility of vertical HIV transmission in the pediatric population. Unfortunately, the data of the prevalence of HIV and associated risk factors in these populations remain limited in Rwanda. The study aimed to assess HIV prevalence and risk factors for infants born to mothers on ARV treatment at CHUB/Rwanda. MethodsA cross-sectional study was carried out on infants who were born to mothers under ARV treatment at CHUB. The associated risk factors were retrospectively assessed using prevention vertical HIV transmission records, and Dried Blood spots (DBS) were prospectively tested using Polymerase Chain Reaction (PCR). Data were analyzed by logistic regression. Ethical clearance (Ref: CMHS/IRB/198/2017) was issued by University of Rwanda to fulfill research ethical consideration.ResultsAmong 185(100%) infants born to HIV-positive mothers under ARV treatment, 5(2.7%) were HIV positive. The most associated risk factors were increased to over 1log copies/ml mother’s viral load (OR 9.3, 95% CI 1.01-85.45, P= 0.04) and mother’s CD4 count lower than 350 cells/µl (OR 6.4, 95% CI 1.03-40.06, P=0.04). The factors found to reduce the rate of vertical transmission of HIV were health facility as a delivery place (P=0.03), exclusive breastfeeding for 6 months (P= 0.006), and attending the antenatal care (P=0.01) while feeding children and vaginal delivery were associated risks but not statistically significant.ConclusionThe current study supports that the more mothers’ viral load and CD4 count decrease, so does the risk of HIV to their infants. A fact which indicates that both prevalence and risk factors remain an alarming issue. Much effort and multi-disciplinary approach are highly recommended.

29 July 2021 in Preprints.org
Verified
Preprint
Open access
BNBernard Nsengimana
Bernard Nsengimana
YJYu Jin
Yu Jin
YJYuting Jia
Yuting Jia
WWWenqiang Wei
Wenqiang Wei
SJShaoping Ji
Shaoping Ji
Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To contain the virus, numerous preventive measures have been taken including isolation of patients, careful infection control, social distancing, and taking vaccine. So far, new confirmed and death cases are still increasing. SARS-CoV-2 invades cells by using the angiotensin converting enzyme 2 (ACE2). ACE2 is an essential enzyme of the renin-angiotensin system (RAS) which converts angiotensin II (Ang II) to angiotensin (1-7). ACE2 is expressed in different organs, including lung, heart, and kidney. A high number of COVID-19 patients developed kidney injury has been reported. Renal impairment and acute injury are associated with mortality of COVID-19, which is 14-16 times higher than other general patients. Acute Kidney Injury has been occured in 2.9 up to 43% of intensive care unit patients. The increasing evidence show that the components of RAS can activate the complement cascade, and cytokines production. Kidney injury caused by SARS-CoV-2 is related mainly to systemic and local inflammation. Moreover, the uncontrolled immune responses mediated by SARS-CoV-2 including hypercytokinaemia, secondary hemophagocytic lymphohistiocytosis, antibody dependent enhancement, complement system, and phagocytic cells activation can contribute in the virus pathogenesis leading to associated renal dysfunction. However, the role and crosstalk between of RAS components and immune response in mediating kidney injury remain undefined. In this review, we focus on the recent studies to provide the pathogenesis of SARS-CoV-2 interacting with RAS and immune responses to mediate kidney injury.